EMA Grants Orphan Drug Designation to ChemiCare’s CIC-39 Molecule

13 May 2022

Corporate

/

ChemiCare’s molecule has received EMA orphan drug designation for rare diseases related to SOCE alterations.

Yesterday, May 12, 2022, ChemiCare‘s reference molecule CIC-39, a startup in our network, received orphan drug designation from the European Medicines Agency (EMA) for the treatment of a group of rare genetic diseases associated with Store-Operated Calcium Entry (SOCE) alterations. These include tubular aggregate myopathy, Stormorken syndrome, and York syndrome.

According to the very promising data collected so far, CIC-39 restores intracellular calcium to physiological levels and counters the two main symptoms of these diseases: muscle damage and platelet dysfunction. These effects make it a promising therapeutic strategy for these patients.

“We are extremely pleased with this designation that allows ChemiCare to have the support of the EMA in the next phases of preclinical and clinical studies development, and on the other hand to access dedicated funding for innovative therapeutic strategies in rare diseases.”
Beatrice Riva, CEO, ChemiCare

“The EMA designation to ChemiCare represents a turning point in the startup’s development program and a significant success of our Business Nursery^TM. We are happy to have ChemiCare within our startup ecosystem and look forward to working alongside strategic partners to develop ChemiCare’s assets.”comunica
Pietro Conti, CEO, Bio4Dreams

See the press release for the initiative Download

Altri aggiornamenti

1 Jul 24

Portfolio

Friuli Venezia Giulia in Milan with the Select FVG Agency at Bio4Dreams

EMA Grants Orphan Drug Designation to ChemiCare’s CIC-39 Molecule

13 May 2022

Corporate

/

ChemiCare’s molecule has received EMA orphan drug designation for rare diseases related to SOCE alterations.

Yesterday, May 12, 2022, ChemiCare‘s reference molecule CIC-39, a startup in our network, received orphan drug designation from the European Medicines Agency (EMA) for the treatment of a group of rare genetic diseases associated with Store-Operated Calcium Entry (SOCE) alterations. These include tubular aggregate myopathy, Stormorken syndrome, and York syndrome.

According to the very promising data collected so far, CIC-39 restores intracellular calcium to physiological levels and counters the two main symptoms of these diseases: muscle damage and platelet dysfunction. These effects make it a promising therapeutic strategy for these patients.

“We are extremely pleased with this designation that allows ChemiCare to have the support of the EMA in the next phases of preclinical and clinical studies development, and on the other hand to access dedicated funding for innovative therapeutic strategies in rare diseases.”
Beatrice Riva, CEO, ChemiCare

“The EMA designation to ChemiCare represents a turning point in the startup’s development program and a significant success of our Business Nursery^TM. We are happy to have ChemiCare within our startup ecosystem and look forward to working alongside strategic partners to develop ChemiCare’s assets.”comunica
Pietro Conti, CEO, Bio4Dreams

See the press release for the initiative Download

Altri aggiornamenti

1 Jul 24

Portfolio

Call4Ideas FVG: award for best innovative idea to BrainDTech and BioChiCa

27 Jun 24

Events

Workshop: presentation of support measures for the FVG Life Sciences ecosystem

26 Jun 24

Partnerships

Partnership with the University of Udine – Department of Medicine (DMED)

25 Jun 24

Memberships

Needleye Robotics joins the Bio4Dreams ecosystem

21 Jun 24

Memberships

Friuli Venezia Giulia in Milan with the Select FVG Agency at Bio4Dreams

EMA Grants Orphan Drug Designation to ChemiCare’s CIC-39 Molecule

13 May 2022

Corporate

/

ChemiCare’s molecule has received EMA orphan drug designation for rare diseases related to SOCE alterations.

Yesterday, May 12, 2022, ChemiCare‘s reference molecule CIC-39, a startup in our network, received orphan drug designation from the European Medicines Agency (EMA) for the treatment of a group of rare genetic diseases associated with Store-Operated Calcium Entry (SOCE) alterations. These include tubular aggregate myopathy, Stormorken syndrome, and York syndrome.

According to the very promising data collected so far, CIC-39 restores intracellular calcium to physiological levels and counters the two main symptoms of these diseases: muscle damage and platelet dysfunction. These effects make it a promising therapeutic strategy for these patients.

“We are extremely pleased with this designation that allows ChemiCare to have the support of the EMA in the next phases of preclinical and clinical studies development, and on the other hand to access dedicated funding for innovative therapeutic strategies in rare diseases.”
Beatrice Riva, CEO, ChemiCare

“The EMA designation to ChemiCare represents a turning point in the startup’s development program and a significant success of our Business Nursery^TM. We are happy to have ChemiCare within our startup ecosystem and look forward to working alongside strategic partners to develop ChemiCare’s assets.”comunica
Pietro Conti, CEO, Bio4Dreams

See the press release for the initiative Download

Altri aggiornamenti

1 Jul 24

Portfolio

Call4Ideas FVG: award for best innovative idea to BrainDTech and BioChiCa

27 Jun 24

Events

Workshop: presentation of support measures for the FVG Life Sciences ecosystem

26 Jun 24

Partnerships

Partnership with the University of Udine – Department of Medicine (DMED)

25 Jun 24

Memberships

Needleye Robotics joins the Bio4Dreams ecosystem

21 Jun 24

Memberships

Friuli Venezia Giulia in Milan with the Select FVG Agency at Bio4Dreams

EMA Grants Orphan Drug Designation to ChemiCare’s CIC-39 Molecule

13 May 2022

Corporate

/

ChemiCare’s molecule has received EMA orphan drug designation for rare diseases related to SOCE alterations.

Yesterday, May 12, 2022, ChemiCare‘s reference molecule CIC-39, a startup in our network, received orphan drug designation from the European Medicines Agency (EMA) for the treatment of a group of rare genetic diseases associated with Store-Operated Calcium Entry (SOCE) alterations. These include tubular aggregate myopathy, Stormorken syndrome, and York syndrome.

According to the very promising data collected so far, CIC-39 restores intracellular calcium to physiological levels and counters the two main symptoms of these diseases: muscle damage and platelet dysfunction. These effects make it a promising therapeutic strategy for these patients.

“We are extremely pleased with this designation that allows ChemiCare to have the support of the EMA in the next phases of preclinical and clinical studies development, and on the other hand to access dedicated funding for innovative therapeutic strategies in rare diseases.”
Beatrice Riva, CEO, ChemiCare

“The EMA designation to ChemiCare represents a turning point in the startup’s development program and a significant success of our Business Nursery^TM. We are happy to have ChemiCare within our startup ecosystem and look forward to working alongside strategic partners to develop ChemiCare’s assets.”comunica
Pietro Conti, CEO, Bio4Dreams

See the press release for the initiative Download